Luis Diaz Jr. discusses the potential of immunoablative neoadjuvant therapy at CICON24 – CRI

CRI (Cancer Research Institute) shared a post on LinkedIn:

”During the first session of CICON24, Memorial Sloan Kettering Cancer Center’s Dr. Luis Diaz Jr. dove into the groundbreaking potential of immunoablative neoadjuvant therapy. This innovative approach uses the power of the immune system to target and shrink tumors to a manageable size before surgery, offering new hope to patients in the fight against cancer. ‘The expectation isn’t to shrink the tumor a little bit. The expectation isn’t just to do cool science,’ he emphasizes. ‘The expectation is to transform these patients’ lives.”’

Watch attached video.
Source: CRI/LinkedIn

CICON24 (2024 International Cancer Immunotherapy Conference) was organized by the Cancer Research Institute (CRI) and the European Network for Cancer Immunotherapy (ENCI). Held from September 8-11, 2024 in National Harbor, MD, the conference focused on the theme “Translating Science into Survival.” It featured over 60 talks from leaders in cancer immunology and immunotherapy, exploring a wide range of advancements in the field.

Luis Diaz Jr., MD, serves as the Head of the Division of Solid Tumor Oncology within the Department of Medicine at Memorial Sloan Kettering Cancer Center. He specializes in advanced colon and pancreatic cancers. Dr. Diaz has conducted research on the development of a liquid biopsy, a tool used for detecting cancer and monitoring its response to treatment. Luis Diaz is also a Member of the Board of Directors at Quest Diagnostics, a Member of the National Cancer Advisory Board at The White House and Co-Founder of Pagerbox.